
Lauren A Peters, PhD
About Me
Lauren Peters, M.A., Ph.D, is an Assistant Professor in the Department of Genetics and Genomic Sciences and a faculty member of the Icahn Genomics Institute. Dr. Peters was trained in immunology, genetics and computational biology. Her research focuses on the discovery of how rare and common genetic drivers of known immune mediated and as yet, unknown, immune drivers of other systemic and organ specific diseases, function in pathology. Her research is applied to the design of next generation in silico models of disease by the integration of clinical electronic medical record with multi-omics profiling of the disease tissue from specific patient populations. Through this approach, she defines patient data driven mechanisms of disease pathogenesis and identification of novel patient subsets, biomarkers and approaches to therapeutic discovery with disease target phenotyping and experimental validation. Dr. Peters also led the Disease Discovery group at Sema4, a patient centric health company since 2017. Prior to joining Mount Sinai, Dr. Peters was a scientist in oncology therapeutic discovery in the Cell Biology group at Imclone Systems, Eli Lilly and worked in business development at Regeneron. Dr. Peters has worked in Information Technology at Barclays and management consulting at Kaiser Associates where she advised Fortune 100 clients in the pharmaceutical, technology, consumer products, and aerospace and defense industries on business strategy.
Language
Position
Research Topics
Autoimmunity, Bioinformatics, Computational Biology, Drug Design and Discovery, Genomics, Immune Deficiency, Inflammation, Inflammatory Bowel Disease (IBD), Mucosal Immunology
About Me
Lauren Peters, M.A., Ph.D, is an Assistant Professor in the Department of Genetics and Genomic Sciences and a faculty member of the Icahn Genomics Institute. Dr. Peters was trained in immunology, genetics and computational biology. Her research focuses on the discovery of how rare and common genetic drivers of known immune mediated and as yet, unknown, immune drivers of other systemic and organ specific diseases, function in pathology. Her research is applied to the design of next generation in silico models of disease by the integration of clinical electronic medical record with multi-omics profiling of the disease tissue from specific patient populations. Through this approach, she defines patient data driven mechanisms of disease pathogenesis and identification of novel patient subsets, biomarkers and approaches to therapeutic discovery with disease target phenotyping and experimental validation. Dr. Peters also led the Disease Discovery group at Sema4, a patient centric health company since 2017. Prior to joining Mount Sinai, Dr. Peters was a scientist in oncology therapeutic discovery in the Cell Biology group at Imclone Systems, Eli Lilly and worked in business development at Regeneron. Dr. Peters has worked in Information Technology at Barclays and management consulting at Kaiser Associates where she advised Fortune 100 clients in the pharmaceutical, technology, consumer products, and aerospace and defense industries on business strategy.
Language
Position
Research Topics
Autoimmunity, Bioinformatics, Computational Biology, Drug Design and Discovery, Genomics, Immune Deficiency, Inflammation, Inflammatory Bowel Disease (IBD), Mucosal Immunology
Education
BA, Boston University
MA, Columbia University
PhD, Icahn School of Medicine at Mount Sinai
Locations
Publications
Selected Publications
- A temporal classifier predicts histopathology state and parses acute-chronic phasing in inflammatory bowel disease patients. Lauren A. Peters, Joshua R. Friedman, Aleksandar Stojmirovic, Jacob Hagen, Sander Houten, Tetyana Dodatko, Mariana P. Amaro, Paula Restrepo, Zhi Chai, J. Rodrigo Mora, Holly A. Raymond, Mark Curran, Radu Dobrin, Anuk Das, Huabao Xiong, Eric E. Schadt, Carmen Argmann, Bojan Losic. Communications Biology
- Biopsy and blood-based molecular biomarker of inflammation in IBD. Carmen Argmann, Ruixue Hou, Ryan C. Ungaro, Haritz Irizar, Zainab Al-Taie, Ruiqi Huang, Roman Kosoy, Swati Venkat, Won Min Song, Antonio F. Di'narzo, Bojan Losic, Ke Hao, Lauren Peters, Phillip H. Comella, Gabrielle Wei, Ashish Atreja, Milind Mahajan, Alina Iuga, Prerak T. Desai, Patrick Branigan, Aleksandar Stojmirovic, Jacqueline Perrigoue, Carrie Brodmerkel, Mark Curran, Joshua R. Friedman, Amy Hart, Esi Lamousé-Smith, Jan Wehkamp, Saurabh Mehandru, Eric E. Schadt, Bruce E. Sands, Marla C. Dubinsky, Jean Frederic Colombel, Andrew Kasarskis, Mayte Suárez-Fariñas. Gut
- An Integrated Taxonomy for Monogenic Inflammatory Bowel Disease. Chrissy Bolton, Christopher S. Smillie, Sumeet Pandey, Rasa Elmentaite, Gabrielle Wei, Carmen Argmann, Dominik Aschenbrenner, Kylie R. James, Dermot P.B. McGovern, Marina Macchi, Judy Cho, Dror S. Shouval, Jochen Kammermeier, Sibylle Koletzko, Krithika Bagalopal, Melania Capitani, Athena Cavounidis, Elisabete Pires, Carl Weidinger, James McCullagh, Peter D. Arkwright, Wolfram Haller, Britta Siegmund, Lauren Peters, Luke Jostins, Simon P.L. Travis, Carl A. Anderson, Scott Snapper, Christoph Klein, Eric Schadt, Matthias Zilbauer, Ramnik Xavier, Sarah Teichmann, Aleixo M. Muise, Aviv Regev, Holm H. Uhlig. Gastroenterology
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Dr. Peters has not yet completed reporting of Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Dr. Peters has not yet completed reporting of Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.